Membranous nephropathy associated with the use of levodopa-carbidopa combination

Membranous Nephropathy Associated with Atheroembolism

Membranous nephropathy (MN) is one of the most common biopsy diagnoses in adults, and it has been associated with chronic infections, autoimmune diseases, malignancies, and drugs. However, MN associated with cholesterol crystal emboli has never been reported. Here we present a patient with MN as an unusual manifestation of atheroembolism. A 75-year-old man with worsening renal function after ca...

Membranous Nephropathy Associated with Tuberculosis

Correspondence To the Editor: Glomerulonephritis (GN) due to Mycobacterium tuberculosis (M. tuberculosis) is rare, [1] and membranous nephropathy (MN) associated with tuberculosis is seldom reported. Because of atypical and nonspecific manifestations, tuberculosis‑associated GN (TB‑GN) is difficult to diagnose. Patients usually present with hematuria, proteinuria, edema, and varying degrees of ...

Membranous nephropathy PLA2R+ associated with Chagas disease

Chagas disease (CD) - a tropical parasitic disease caused by the protozoan Trypanosoma cruzi - is a major health problem in Latin America. The immune response against the parasite is responsible for chronic CD lesions. Currently, there are no reports of an association between CD and membranous nephropathy (MN). The detection of the phospholipase A2 receptor (PLA2R) as a target antigen in idiopa...

Pulmonary tuberculosis associated with membranous nephropathy.

Comparison of the pharmacokinetics of an oral extended‐release capsule formulation of carbidopa‐levodopa (IPX066) with immediate‐release carbidopa‐levodopa (Sinemet®), sustained‐release carbidopa‐levodopa (Sinemet® CR), and carbidopa‐levodopa‐entacapone (Stalevo®)

IPX066 (extended-release carbidopa-levodopa [ER CD-LD]) is an oral extended-release capsule formulation of carbidopa and levodopa. The single-dose pharmacokinetics of ER CD-LD (as 2 capsules; total dose, 97.5 mg-390 mg CD-LD) versus immediate-release (IR) CD-LD (25 mg-100 mg), sustained-release (CR) CD-LD (25 mg-100 mg), and CD-LD-entacapone (25 mg-100 mg-200 mg) was evaluated in healthy subjec...